(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
South African radio presenter among five charged over Russia recruitment plot - 2$1,000 bribes, Mormon momfluencer mixers and making content to get plastic surgery: The wildest things I learned reporting my book
- 3The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- 4Rediscovering Experience Through Excursions: Individual Travel Stories
- 5Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
- First SpaceX booster for upgraded Starship fails during test in Texas
- Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- ‘And then we saw the little head.’ Scientists witness rare sperm whale birth
- What to watch for as NASA’s historic Artemis II crew prepares to lift off toward the moon
- 'Always put others first': IDF reservist who died while on leave saves four with organ transplants
- The best overlooked performances of 2025
- Top Frozen yogurt Flavor: Cast Your Vote!
- I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
